European journal of clinical investigation
-
Eur. J. Clin. Invest. · Feb 2023
Randomized Controlled Trial Multicenter StudyEarly administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial.
Controversies on sub-populations most sensitive to therapy and the best timing of starting the treatment still surround the use of immunomodulatory drugs in COVID-19. ⋯ High-dose tofacitinib therapy in patients with COVID pneumonitis is safe and may prevent deterioration to respiratory failure.